FLU IVIG


Study Description: This study is to treat influenza (flu). For most people flu is usually mild, but it can cause serious illness or death. One possible new treatment for severe flu is to use immune responses (called antibodies). This study uses antibodies taken from people who had the flu and got better, or who had a good response to a flu vaccine. Antibodies fight infection. Giving these antibodies, called intravenous immunoglobulin or IVIG, to people in the hospital for flu, may help to treat flu. We want to see if it help in three ways: 1) to help get better sooner, 2) to be able to get out of the hospital sooner, 3) to have fewer bad effects from the flu. IVIG is not approved for treating the flu. We are testing it in this study. Half the people in the study will get one dose of IVIG while in the hospital, half will get one dose of placebo (no real IVIG in it), and we will not know which patient gets IVIG or placebo. We will get blood and deep nasal swabs from all study patients, and collect medical information up through 28 days after getting their IVIG/placebo.

Contact for Enrollment

    
     (706) 723-0106
    mfarrough@augusta.edu

    Submit Information Online

Principal Investigator: Rodger MacArthur

Eligibility Criteria: 1. Adults age 18 years or older. 2. Confirmed influenza 3. Being hospitalized for treatment of influenza with expected stay of at least 24 hours 4. No pregnant or breastfeeding women

Compensation: Yes, subjects will be compensated.

Compensation Explanation: The ClinCard system will be used for stipend payments to study subjects. Payments will be: For Days 0, 1, and 3, subjects will receive $50.00 per visit. For Day 7, they will receive $100.00 For follow-up calls Days 14 and 28 they will receive $25.00 per call. Acknowledged that a W-9 from each subject will be required, as total compensation is over $100.

 

Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.